New societal guidelines recommend subcutaneous implantable cardioverter-defibrillator for patients with ventricular arrhythmias at risk of sudden cardiac death. -Boston Scientific
Updated guidelines issued by the American Heart Association (AHA), the American College of Cardiology (ACC) and the Heart Rhythm Society (HRS) now formally recommend the use of a subcutaneous implantable cardioverter-defibrillator (S-ICD) for the treatment of patients with ventricular arrhythmias and the prevention of sudden cardiac death. The Boston Scientific EMBLEM MRI S-ICD System is the only S-ICD on the market, and the only implantable defibrillator available that provides protection for patients at risk of sudden cardiac death without touching the heart.
Co-published in Circulation, the Journal of the American College of Cardiology (JACC) and the Heart Rhythm Journal (HRJ), the "2017 AHA/ACC/HRS Guideline for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death" supports the use of an S-ICD device with a Class IIa recommendation for all patients who meet the criteria for an implantable cardioverter-defibrillator (ICD) without a need for pacing. The guidelines also strongly recommend the use of an S-ICD device as the standard of care with a Class I recommendation for the subset of these patients who have inadequate vascular access or are at high risk for infection, including those with diabetes mellitus. Patients at high risk for infection often have limited venous access which can result in a prolonged or failed implantation of a transvenous ICD (TV-ICD).
Per a recent analysis of more than 6,400 patients, those implanted with TV-ICD were at an eight-fold higher rate of lead complications than patients who received an S-ICD device. Earlier this year, the HRS recommended private health insurance companies update any limited or unavailable coverage to ensure all patients with appropriate clinical rationale have access to therapy with the S-ICD device. Positive coverage policies for the S-ICD System have been established by the Centers for Medicare and Medicaid Services and private payers representing more than 90% of insured individuals in the U.S. The S-ICD System is included in the European Society of Cardiology guidelines, published in 2015, for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death.
Related news and insights
Fabhalta is a Factor B inhibitor that acts proximally in the alternative complement pathway of the immune system, providing comprehensive control of red blood cell (RBC) destruction within and outside the blood vessels (intra- and extravascular hemolysis [IVH and EVH])
Merck KGaA, a leading science and technology company, announced that its two Phase III EVOLUTION clinical trials (evolution RMS 1 and evolution RMS 2) investigating the efficacy and safety of evobrutinib did not meet their primary endpoints of reducing annualized relapse rates (ARR) in people with relapsing multiple sclerosis (RMS) compared to oral teriflunomide (Aubagio) (0.11 vs. 0.11 in evolution RMS 1 and 0.15 for evobrutinib vs. 0.14 for teriflunomide in evolution RMS 2, p=NS in both trials)